Skip Navigation

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.

 

COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

Daniel W. Chan, Ph.D.

Headshot of Daniel W. Chan
  • Director of Clinical Chemistry Division
  • Professor of Pathology

Research Interests

Immunoassay; Biochemical Tumor Markers - Particularly Breast and Prostate Tumor Makers; Clinical Chemistry; Proteomics ...read more

Background

Daniel W. Chan, Ph.D., DABCC, FACB (2021)

Dr. Daniel W. Chan is Professor of Pathology, Oncology, Radiology and Urology, the Director of Center for Biomarker Discovery and Translation at the Johns Hopkins University. He is also the Director of Clinical Chemistry Division and the Co-Director of Pathology Core Laboratory at the Johns Hopkins Hospital, Baltimore, Maryland, USA.

Dr. Chan is a diplomat of the American Board of Clinical Chemistry (ABCC) and a fellow of the National Academy of Clinical Biochemistry (NACB). He is an internationally recognized expert in cancer biomarkers, clinical proteomics and molecular diagnostics.  He has written 5 books, 40 book chapters and over 300 scientific articles. He is funded by the National Cancer Institute (NCI) as the Principal investigator of the CPTAC (Cancer Proteomic Tumor Analysis Consortium) and the Biomarker Reference Lab for the EDRN (Early Detection Research Network).

The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, and ovarian cancer biomarkers. In 1977, he conducted the clinical study of CA27.29 as a marker for breast cancer recurrence leading to the first FDA approval of a serum breast cancer assay. In 2000, he founded the Center for Biomarker Discovery and Translation. The focus of this Center is the discovery of proteomics biomarkers using mass spectrometry and protein microarrays, followed by the validation and translation of these novel biomarkers for the detection, diagnosis, classification, management and understanding of human diseases.  In 2009, he developed the OVA1 test for ovarian cancer – the first FDA cleared proteomic in vitro diagnostic multivariate index assay (IVDMIA). In 2012, he developed public-private partnerships (NCI EDRN, industry and academic centers) leading to the clinical study, publication and FDA approval of new prostate cancer tests – proPSA (phi) with Beckman Coulter Inc. and PCA3 (PROGENSA) with Gen-probe (Hologic, Inc).

Dr. Chan has trained over 30 clinical chemistry fellows at Johns Hopkins. Many of these scientists have become leaders and professor in Clinical Chemistry. During the last 20 years, he has given over two hundred invited lectures, both within and outside of US.

Dr. Chan received numerous awards for his outstanding contributions to clinical chemistry. Examples are the inaugural Morton K. Schwartz Award for Cancer Research Diagnostics, Albert Nichols Award for strategic innovation in laboratory medicine, Norman Kubasik Award for Outstanding contribution to the education of clinical laboratory scientists, Bernard Gerulat Award for outstanding achievement in clinical chemistry, Carl R. Joliff Award for Outstanding achievement in diagnostic immunology and education, Miriam Reiner Award for outstanding contributions to research in the field of clinical chemistry and Outstanding Contribution to Clinical Chemistry in Research Award (all from the AACC). Outstanding Leadership Award (NCI-EDRN), inaugural Translational Proteomics Award (HUPO). He served as the Chair of the Proteomics Division (a founder) of the American Association for Clinical Chemistry (AACC), Board of Directors of NACB and as the President of the National Registry in Clinical Chemistry (NRCC), President of the International Society of Enzymology (ISE) and on the Board of Directors (a founder) of the US Human Proteome Organization (HUPO). He is the Editor-in-Chief of the journal Clinical Proteomics.

...read more

Titles

  • Director of Clinical Chemistry Division
  • Co-Director of Pathology Core Lab
  • Professor of Pathology
  • Professor of Oncology
  • Professor of Radiology and Radiological Science
  • Professor of Urology

Departments / Divisions

Centers & Institutes

Research & Publications

Research Summary

The focus of Dr. Chan's research is the development and application of proteomic and immunologic techniques in the diagnosis, management, and understanding of cancer. His work has demonstrated the importance of analytical methodologies for tumor markers, endocrine or clinical chemistry assays to determine the clinical outcomes of a patient?s disease process.

He is an internationally recognized expert in immunoassay, clinical proteomics, and biochemical tumor markers, particularly prostate, breast and ovarian cancer biomarkers.

He has edited and written five books on immunoassay, immunoassay automation, diagnostic endocrinology, and tumor markers. Dr. Chan has published over 200 articles including the tumor markers chapters in the Tietz Textbook of Clinical Chemistry and in Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, which he also co-edited.

Dr. Chan is actively involved in the Human Proteome Organization (HUPO) and its Plasma Proteome Initiative. He serves as chairman of a HUPO committee responsible for the development of reference specimens for a global comprehensive study of the human proteome.

Selected Publications

Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, Partin AW, Srivastava S, Thompson IM, Wei JT, Zhang Z, and Chan DW. A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [-2]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness. Cancer Epidemiol Biomarkers Prev., 19(5):1193-200, 2010

Füzéry AK, Levin J, Chan MM and Chan DW. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics 2013, 10:13. PMID: 24088261

Hui Zhang*, Tao Liu*, Zhen Zhang*, Samuel H Payne*, Bai Zhang, Jason E McDermott, Jian-Ying Zhou, Vladislav A Petyuk, Li Chen, Debjit Ray, Shisheng Sun, Feng Yang, Lijun Chen, Jing Wang, Punit Shah, Seong Won Cha, Paul Aiyetan, Sunghee Woo, Yuan Tian, Marina A Gritsenko, Therese R Clauss, Caitlin Choi, Matthew E Monroe, Stefani Thomas, Song Nie, Chaochao Wu, Ronald J Moore, Kun-Hsing Yu, David L Tabb, David Fenyö, Vineet Bafna, Yue Wang, Henry Rodriguez, Emily S Boja, Tara Hiltke, Robert C Rivers, Lori Sokoll, Heng Zhu, Ie-Ming Shih, Leslie Cope, Akhilesh Pandey, Bing Zhang, Michael P Snyder, Douglas A Levine, Richard D Smith, Daniel W Chan*#, Karin D Rodland*#, and the CPTAC investigators Integrated proteogenomic characterization of human high grade serous ovarian cancer. Cell 2016  July 28;166(3):755-65. PMID: 27372738. *equal contribution, #corresponding author

Ventzislava A. Hristova, Daniel W. Chan. Cancer biomarker discovery and translation: proteomics and beyond. Expert Review of Proteomics, 2019, Volume 16:2, 93-103

Clark DJ, Dhanasekaran SM, Petralia F, Pan J, Song X, Hu Y, da Veiga Leprevost F, Reva B, Lih TM, Chang HY, Ma W, Huang C, Ricketts CJ, Chen L, Krek A, Li Y, Rykunov D, Li QK, Chen LS, Ozbek U, Vasaikar S, Wu Y, Yoo S, Chowdhury S, Wyczalkowski MA, Ji J, Schnaubelt M, Kong A, Sethuraman S, Avtonomov DM, Ao M, Colaprico A, Cao S, Cho KC, Kalayci S, Ma S, Liu W, Ruggles K, Calinawan A, Gümüş ZH, Geiszler D, Kawaler E, Teo GC, Wen B, Zhang Y, Keegan S, Li K, Chen F, Edwards N, Pierorazio PM, Chen XS, Pavlovich CP, Hakimi AA, Brominski G, Hsieh JJ, Antczak A, Omelchenko T, Lubinski J, Wiznerowicz M, Linehan WM, Kinsinger CR, Thiagarajan M, Boja ES, Mesri M, Hiltke T, Robles AI, Rodriguez H, Qian J, Fenyö D, Zhang B, Ding L, Schadt E, Chinnaiyan AM, Zhang Z, Omenn GS, Cieslik M*, Chan DW*, Nesvizhskii AI*, Wang P*, Zhang H*; Clinical Proteomic Tumor Analysis Consortium. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell. 2019 Oct 31;179(4):964-983.e31. doi: 10.1016/j.cell.2019.10.007. Erratum in: Cell. 2020 Jan 9;180(1):207. *Correspondence authors with equal contribution

Contact for Research Inquiries

Email me Phone: 410-955-2674
Is this you? Edit Profile
back to top button